Abstract
In a double-blind clinical study, electrocardiogram, blood pressure and systolic time intervals were measured in 40 depressive patients treated with either paroxetine (30 mg/day) or amitriptyline (150 mg/day) for 6 weeks. While amitriptyline significantly increased the heart rate, the QTc interval and the PEP/LVET ratio, paroxetine did not alter any of the cardiovascular parameters measured.
Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Similar content being viewed by others
References
Battegay R, Hager M, Rauchfleisch U (1985) Double-blind comparative study of paroxetine and amitriptyline in depressed patients of a university psychiatric outpatient clinic (pilot study). Neuropsychobiology 13:31–37
Borup C, Meidahl B, Petersen I-M, Vangtorp A, le Fevre Honore P (1982) An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness. Pharmacopsychiatry 15:183–186
Burckhardt D, Raeder E, Müller V, Imhof P, Neubauer H (1978) Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 239:213–216
Burgess CD, Montgomery S, Wadsworth J, Turner P (1979) Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients. Postgrad Med J 55:704–708
Edwards JG, Goldie A, Papayanni-Papasthatis S (1989) Effect of paroxetine on the electrocardiogram. Psychopharmacology 97:96–98
Feighner JP, Boyer WF (1989) Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand [Suppl 350] 80:125–129
Giardina EV, Bigger JT, Glassman AH, Perel JM, Kantor SJ (1979) The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation 60:1045–1052
Goldman LS, Alexander RC, Luchins DJ (1986) Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. J Clin Psychiatry 47:225–229
Hamilton TC, Norton J, Poyser RH, Thormählen D (1986) Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals. Drug Res 36:460–463
Kuhs H, Rudolf GAE (1989) A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr Scand [Suppl 350] 80:145–146
Lewis RP, Rittger PR, Forrester WF, Boudoulas H (1977) A critical review of the systolic time intervals. Circulation 56:146–158
Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram IF (1982) Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man. Acta Pharmacol Toxicol 51:351–357
McCelland GR, Raptopoulos P (1985) Cardiovascular effects of paroxetine and amitriptyline after repeated administration to normal volunteers. Br J Clin Pharmacol 20:282
Mertens C, Pintens H (1988) Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin. Acta Psychiatr Scand 77:683–688
Merwe van der TJ, Silverstone T, Ankier SI, Warrington SJ, Turner P (1984) A double-blind non-crossover placebo-controlled study between group comparison of trazodone and amitriptyline on cardiovascular function in major depressive disorder. Psychopathology [Suppl 2] 17:64–76
Montgomery S (1980) The effect of mianserin on sleep and cardiac function. Curr Med Res Opin [Suppl] 6:23–28
Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C (1989) A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatr Scand [Suppl 350] 80:117–123
Roose SP, Glassman AH, Giardina EGV, Walsh BT, Woodring S, Bigger T (1987) Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 44:273–275
Roose SP, Glassman AH, Dalack GW (1989) Depression, heart disease, and tricyclic antidepressants. J Clin Psychiatry [Suppl] 50:12–16
Thomas DR, Nelson DR, Johnson AM (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93:193–200
Tyrer P, Marsden CA, Casey P, Seivewright N (1987) Clinical efficacy of paroxetine in resistant depression. J Psychopharmacol 1:251–257
Weissler AM, Harris WS, Schoenfeld CD (1969) Bedside technics for the evaluation of ventricular function. Am J Cardiology 23:577–583
Warrington SJ, Dana-Haeri J, Sinclair AJ (1989) Cardiovascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and placebo in healthy men. Acta Psychiatr Scand [Suppl 350] 80:42–44
Yokota S, Ishikura Y, Ono H (1987) Cardiovascular effects of paroxetine, a newly developed antidepressant, in anaesthetised dogs in comparison with those of imipramine, amitriptyline and clomipramine. Jpn J Pharmacol 45:335–342
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kuhs, H., Rudolf, G.A.E. Cardiovascular effects of paroxetine. Psychopharmacology 102, 379–382 (1990). https://doi.org/10.1007/BF02244107
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244107